

KORESPONDENSI “Effects of andr”ographolide on p53 and Ki67 expression in an experimental mouse model of endometriosis”

Article Revision Letter for Authors - (JABET-2026-096) External Inbox x



Journal of Advanced Biotechnology and Experimental Therapeutics

to me ▼

Wed, Jul 22, 2:18 PM



Dear Indra Adi Susianto,

Your manuscript entitled "Andrographolide Modulates Macrophage Polarization and Inflammatory-Angiogenic Pathways in an Experimental Endometriosis Model" (Ms.Nr. JABET-2026-096) was reviewed by editorial board members of the Journal of Advanced Biotechnology and Experimental Therapeutics. As initial decision, your manuscript was found interesting but some revisions have to be made before it can reach a publishable value.

Please answer all the comments below point-by-point in an accompanying response letter to your revised submission. And mark any corrections/editing with RED color in text the manuscript.

Within 21 days, you should send your revised manuscript via the online system of eJManager on <https://www.ejmanager.com/my/jabet/>.

Best Regards

Editorial Office

Journal of Advanced Biotechnology and Experimental Therapeutics

jabet.editor@gmail.com or jabet.editor@bsmiab.org

<http://www.ejmanager.com/my/jabet>

<http://www.bsmiab.org/jabet>

COMMENTS for Authors:

=> Reviewer # 1

-The title could be more specific and updated based on findings, and Additional experimental data should be included to keep title as "Andrographolide modulates macrophage polarization and inflammatory-angiogenic pathways in an experimental endometriosis mouse model"

-More than 46% of AI content was found, which should be below 15%

-Methods should be detailed and reproducible.

-The values in Tables 1-2 should be in standard form, such as 2.3345, not 2,3345.

-Treatment group names should be similar throughout the manuscript.

-An editable PPT of all figures is needed to upload (or send an email)

-The end of the discussion should have limitations of the study.

Revised Article Submission

External

Inbox x



Journal of Advanced Biotechnology and Experimental Therapeutics

to me ▾

Thu, Jul 23, 3:19 PM



Dear Indra Adi Susianto,

Your REVISED ARTICLE entitled **Effects of Andrographolide on Ki67 and p53 Expression in an Experimental Balb/C Model of Endometriosis** (Mns No.JABET-2026-096) has been received by **Journal of Advanced Biotechnology and Experimental Therapeutics**.

You could follow status of your manuscript by login to your author account at www.ejmanager.com.

Thank you for submitting your REVISED version of your article.

Best regards,

Editor

Journal of Advanced Biotechnology and Experimental Therapeutics

<https://www.bsmlab.org/jabet>

JOURNAL CONTACT EMAIL: jabet.editor@gmail.com

AUTHOR LOGIN: <https://www.ejmanager.com/my/jabet>

REVIEWER LOGIN: <https://www.ejmanager.com/reviewers/>

EDITOR LOGIN: <https://www.ejmanager.com/editors/>

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email.

#*-----*#

DO YOU WANT TO START YOUR OWN JOURNAL? JUST CONTACT US TO SEE HOW IT IS EASY WITH eJManager.com (info@ejmanager.com).

[AUTHOR TOOLS :: AI-Powered Language Editing and Improvement for scientific articles.](#)

Article Revision Letter for Authors - (JABET-2026-096)

External Inbox x



Journal of Advanced Biotechnology and Experimental Therapeutics

Thu, Jul 30, 3:36 PM



to me ▾

Dear Indra Adi Susianto,

The revisions for your manuscript titled -Effects of Andrographolide on Ki67 and p53 Expression in an Experimental Balb/C Model of Endometriosis- and manuscript number (JABET-2026-096) was reviewed by Editorial Board of Journal of Advanced Biotechnology and Experimental Therapeutics and decided that the following revisions should be done.

Please answer all the comments below, in your answer letter and any editing should be marked as RED text in the manuscript.

Within 2 days, you should send your revised manuscript by journal Submit Article page.

Best Regards

Journal of Advanced Biotechnology and Experimental Therapeutics

jabet.editor@gmail.com or jabet.editor@bsmiab.org

<http://www.ejmanager.com/my/jabet>

<http://www.bsmiab.org/jabet>

Editorial COMMENTS for Authors:

-No point-by-point revision letter was found.

-Discount code SI2026 is applicable for the special issue, not for your article based on scope (Artificial Intelligence in health).

=> Reviewer # 1

-Treatment group names should be similar throughout the manuscript.

=> Reviewer # 2

-In conclusion, andrographolide is a promising therapeutic candidate despite reporting that reductions in Ki67 and p53 were not statistically significant. The conclusions should be moderated to reflect the actual findings and avoid overstating therapeutic efficacy.

-In the discussion, effects of andrographolide on alteration of NF- κ B, MAPK, PI3K/Akt, and inflammatory pathways were mentioned, but none of these signaling molecules were studied here. These mechanistic interpretations should be presented as hypotheses or supported with additional molecular analyses.

-Add a scale bar on the images in Fig 1 and 2 (Send or upload PPT)

Revised Article Submission

External

Inbox x



Journal of Advanced Biotechnology and Experimental Therapeutics

Thu, Jul 30, 5:09 PM



to me ▾

Dear Indra Adi Susianto,

Your REVISED ARTICLE entitled **Effects of Andrographolide on Ki67 and p53 Expression in an Experimental Balb/C Model of Endometriosis** (Mns No:JABET-2026-096) has been received by **Journal of Advanced Biotechnology and Experimental Therapeutics**.

You could follow status of your manuscript by login to your author account at www.ejmanager.com.

Thank you for submitting your REVISED version of your article.

Best regards,

Editor

Journal of Advanced Biotechnology and Experimental Therapeutics

<https://www.bsmlab.org/jabet>

JOURNAL CONTACT EMAIL: jabet.editor@gmail.com

AUTHOR LOGIN: <https://www.ejmanager.com/my/jabet>

REVIEWER LOGIN: <https://www.ejmanager.com/reviewers/>

EDITOR LOGIN: <https://www.ejmanager.com/editors/>

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email.

#*-----*#

DO YOU WANT TO START YOUR OWN JOURNAL? JUST CONTACT US TO SEE HOW IT IS EASY WITH eJManager.com (info@ejmanager.com).

[AUTHOR TOOLS :: AI-Powered Language Editing and Improvement for scientific articles.](#)

Read Proof of Your Article at eJManager - (JABET-2026-096)

External Inbox x



Journal of Advanced Biotechnology and Experimental Therapeutics

to me ▾

Sat, Aug 15, 2:32 PM (8 days ago)



Dear Indra Adi Susianto,

Your article "Effects of Andrographolide on Ki67 and p53 Expression in an Experimental Balb/C Model of Endometriosis" is almost ready for publication at Journal of Advanced Biotechnology and Experimental Therapeutics. But before publication, your final check will be highly appreciated. For this reason, the galley proof of your accepted article was uploaded to your author homepage.

Please log in, download the proof, and check/read **the RED texts carefully**; then submit your corrections latest with the following **48 hours**.

All corrections should be RED in the text. Please also consider that **no changes can be made to your article after this step**.

Note: After the corrected proof is submitted, the "Online first version" of your article will be published soon under the forthcoming issue:

<https://www.bsmiab.org/jabet/articles/forthcoming-issue>.

Best Regards

Journal of Advanced Biotechnology and Experimental Therapeutics

jabet.editor@gmail.com or jabet.editor@bsmiab.org

<http://www.ejmanager.com/my/jabet>

<http://www.bsmiab.org/jabet>

[Link: <http://www.ejmanager.com/my/jabet/>]

JOURNAL CONTACT EMAIL: jabet.editor@gmail.com

AUTHOR LOGIN: <https://www.ejmanager.com/my/jabet>

REVIEWER LOGIN: <https://www.ejmanager.com/reviewers/>

EDITOR LOGIN: <https://www.ejmanager.com/editors/>

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email.

#*-----*#

DO YOU WANT TO START YOUR OWN JOURNAL? JUST CONTACT US TO SEE HOW IT IS EASY WITH eJManager.com (info@ejmanager.com).

[AUTHOR TOOLS :: AI-Powered Language Editing and Improvement for scientific articles.](#)

Decision Letter to Authors - Acceptance - (JABET-2026-096)

External

Inbox x



Journal of Advanced Biotechnology and Experimental Therapeutics

to me ▾

Thu, Jul 30, 5:25 PM



Dear Indra Adi Susianto

I am pleased to inform you that your manuscript titled as "Effects of Andrographolide on Ki67 and p53 Expression in an Experimental Balb/C Model of Endometriosis" (Manuscript Number: JABET-2026-096) was accepted for publication in the Journal of Advanced Biotechnology and Experimental Therapeutics. However, publication of your manuscript will only proceed on the condition that all final files comply with the journal integrity checks. In the event that any file does not comply with our integrity checks, the journal reserves the right to rescind this decision, or, alternatively, you may be contacted to resolve any concerns raised by these checks. Shortly after proof of your article is completed, you will find the online first version of your article on: <https://www.bsmiab.org/jabet/articles/forthcoming-issue>.

You may login to your author account page, and visit the accepted articles section in order to get an official/formal acceptance letter as PDF.

I would like to remind you that you could send your future manuscripts to Journal of Advanced Biotechnology and Experimental Therapeutics.

Sincerely yours,

Md Jamal Uddin, PhD

Editor-in-Chief

Journal of Advanced Biotechnology and Experimental Therapeutics

Website: <https://www.bsmiab.org/jabet/>

Email: jabet.editor@bsmiab.org or

jabet.editor@gmail.com